기사

[Medical Today = Reporter Minseok Choi] Prodizen, a regenerative medicine company, will participate in the 2025 Korean Society of Laser Dermatology and Hair Loss (KALDAT, hereinafter referred to as KALDAT) held at the Grand InterContinental Parnas in Samseong-dong, Seoul on December 14th.

KALDAT is a large-scale academic event in the fields of plastic surgery, dermatology, and laser technology, combining the Aesthetic Medical Device Expo and the 51st Fall International Academic Conference. It serves as a representative platform for exchange, bringing together medical professionals and industry professionals from Korea and abroad.

Prodizen will participate in this conference and operate a booth to introduce GFC-based anti-aging treatments and the latest treatment trends related to stem cells and blood signaling. It will also share its clinical experience directly with medical professionals in the field and engage in various exchanges based on actual application cases, treatment effects, and technological strengths.

In the official presentation session, which will begin at 3:45 PM in Room A, Dr. Oh Myung-jun, CEO of O& Clinic, will speak on the topic, "Signals of Blood Concentrated Stem Cells: Stem Cells and GFC-Based Anti-Aging Treatments."

Dr. Oh has accumulated expertise in the field of skin and aesthetic treatments, proposing personalized anti-aging treatment models based on his extensive clinical experience and research. His presentation will focus on "GFC+," a highly concentrated growth factor-based injection treatment.

GFC+ is a functional medicine anti-aging solution designed to be administered as an intravenous injection of highly concentrated platelet-derived growth factors. It goes beyond improving skin appearance and aims to be a fundamental treatment that delays the aging process itself.

A Prodizen official stated, “This year’s Daepimo conference is a place to share with medical professionals the new direction of functional medicine anti-aging treatment centered on GFC+,” and “We will continue to expand standardized treatment models that can substantially improve patients’ quality of life not only in Korea but also in the global medical market.”

Meanwhile, Prodizen, the first company in Korea to develop PRP tubes and fully introduce PRP procedures into the Korean medical field, has accumulated extensive expertise in cell therapy and blood application devices. Recently, the company has also demonstrated differentiated technological prowess in skin regeneration and anti-aging with its GFC+ kit and full-body anti-aging solution, Rajuniss.

Medical Today Reporter Choi Min-seok (press@mdtoday.co.kr)